Experimental Quintuple Agonist Outperforms Semaglutide in Mouse Obesity Models

An experimental obesity and diabetes drug called GLP-1-GIP-Lani produced greater reductions in body weight, food intake, fat mass, blood sugar and insulin-related problems than GLP-1 and GIP alone when tested in mouse models, according to research published in the journal Nature.

The study, conducted by the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, examined the compound in mice with diabetes-induced obesity, insulin resistance and genetic obesity. It outperformed semaglutide in the same models.

Typical gastrointestinal side effects remained similar to those seen with existing therapies. The drug combines GLP-1 and GIP, two natural hormones that help regulate appetite and blood sugar, with PPAR activity that may improve insulin sensitivity, inflammation, fat metabolism and liver health. Researchers described the approach as a quintuple agonist because it targets five receptor systems.

Professor Timo D. Muller at Helmholtz Munich led the team. He called the drug a "Trojan horse" in a press release. Muller said the incretin component allows the drug to enter target cells and once inside the PPAR "cargo" activates to help the body better use insulin, process fat and reduce inflammation.

"A major advantage is the amount," Muller said. He added that the lower dosage could reduce side effects. " Dr. Balazs told Fox News Digital that this is a novel mechanism because it is not just relying on a higher dose of an existing drug.

He said the quintuple agonist appears to function both as an "appetite brake" and a metabolic engine while directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism. Balazs noted that the study was conducted only on mouse models and there is no human safety or efficacy data.

He added that the study was conducted over a relatively short period of time, so long-term effects cannot be assessed.

Fox News reported that the research offers a promising direction for future weight-loss treatments but emphasized the early stage of development. The Institute for Diabetes and Obesity at Helmholtz Munich published the findings after testing the triple-action compound against standard incretin-based approaches.

The results arrive as demand grows for more effective therapies with potentially fewer side effects than current GLP-1 medications.

Muller’s team highlighted that the PPAR component’s intracellular action distinguishes the candidate from drugs that primarily suppress appetite through higher dosing.